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Abstract
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase
inhibitors have swiftly been adopted as part of current antiretroviral regimens. The purpose of this study was to review the
evidence for integrase inhibitor use in clinical settings.
Methods: MEDLINE and Web-of-Science were screened from April 2006 until November 2012, as were hand-searched
scientific meeting proceedings. Multiple reviewers independently screened 1323 citations in duplicate to identify
randomized controlled trials, nonrandomized controlled trials and cohort studies on integrase inhibitor use in clinical
practice. Independent, duplicate data extraction and quality assessment were conducted.
Results: 48 unique studies were included on the use of integrase inhibitors in antiretroviral therapy-naive patients and
treatment-experienced patients with either virological failure or switching to integrase inhibitors while virologically
suppressed. On the selected studies with comparable outcome measures and indication (n = 16), a meta-analysis was
performed based on modified intention-to-treat (mITT), on-treatment (OT) and as-treated (AT) virological outcome data. In
therapy-naive patients, favorable odds ratios (OR) for integrase inhibitor-based regimens were observed, (mITT OR 0.71, 95%
CI 0.59–0.86). However, integrase inhibitors combined with protease inhibitors only did not result in a significant better
virological outcome. Evidence further supported integrase inhibitor use following virological failure (mITT OR 0.27; 95% CI
0.11–0.66), but switching to integrase inhibitors from a high genetic barrier drug during successful treatment was not
supported (mITT OR 1.43; 95% CI 0.89–2.31). Integrase inhibitor-based regimens result in similar immunological responses
compared to other regimens. A low genetic barrier to drug-resistance development was observed for raltegravir and
elvitegravir, but not for dolutegravir.
Conclusion: In first-line therapy, integrase inhibitors are superior to other regimens. Integrase inhibitor use after virological
failure is supported as well by the meta-analysis. Careful use is however warranted when replacing a high genetic barrier
drug in treatment-experienced patients switching successful treatment.
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Introduction
Since the first reports on Acquired Immunodeficiency Syn-
drome (AIDS), the human immunodeficiency virus (HIV) has
caused a devastating pandemic with yearly 2.6 million new
infections worldwide [1]. The stable integration of the reverse
transcribed viral genome into host chromatin forms an important
point-of-no-return during HIV infection. Raltegravir is the first
representative of a new class of antiretroviral drugs targeting the
strand transfer reaction during this integration process. Strand
transfer integrase inhibitors bind in the catalytic core domain of
the enzyme and compete for binding with host DNA. Introduction
of raltegravir in 2008 appeared almost simultaneously with
approval of second generation drugs of existing therapeutic classes
as the protease inhibitor (PI) darunavir and the non-nucleoside
reverse transcriptase inhibitor (NNRTI) etravirine. Combined use
of these drugs has resulted in high levels of virological suppression
in treatment-experienced populations [2,3]. As a result, the
treatment goals in highly experienced patients have been redefined
towards successful suppression of plasma viral load [4,5]. In
addition to high efficacy, the initial use of this first integrase
inhibitor (INI) also suggested good tolerability, a favorable safety
profile and absence of significant drug-drug interactions. Follow-
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ing this success, raltegravir has been explored in a divergent setting
of clinical indications such as therapy-naive populations, once-
daily formulations, simplification strategies, nucleoside/nucleotide
reverse transcriptase inhibitors sparing regimens and maintenance
therapy. Conflicting results were reported in several clinical
situations, hampering uniform conclusions for successful use of
raltegravir. Meanwhile other INIs with a similar mechanism of
action such as elvitegravir and dolutegravir have been clinically
evaluated. Elvitegravir has been approved in the US and
dolutegravir has entered advanced stages of clinical development
(Table 1). The objective of this study was to perform a systematic
review and meta-analysis of current evidence regarding the use of
integrase inhibitors in various clinical settings.
Methods
Data Sources and Searches
We followed a protocol using the methodological approaches
outlined in the Agency for Healthcare Research and Quality
Methods Guide for Effectiveness and Comparative Effectiveness
Reviews [6] and applied the PRISMA Guidelines [7]. The
systematic literature review aimed at including all published
studies from April 2006 until November 2012 reporting on the
clinical use of INIs for antiretroviral therapy. We searched
MEDLINE and Web-of-Science with the MeSH terms ‘‘integrase
inhibitor’’, ‘‘HIV’’ or ‘‘raltegravir’’ or ‘‘elvitegravir’’ or ‘‘dolute-
gravir’’. We systematically hand-searched the meeting proceedings
(abstract books, trial registries and reference lists) from key
conferences that were held in the same period: the Conference
on Retroviruses and Opportunistic Infections, the European
Workshop on HIV & Hepatitis: Treatment Strategies & Antiviral
Drug Resistance, the International HIV Drug Resistance Work-
shop, the International AIDS Conference, the European AIDS
Conference (EACS), the International Congress on Drug Therapy
in HIV Infection and the Interscience Conference on Antimicro-
bial Agents and Chemotherapy.
Study Selection
The initial selection was performed by two independent
investigators. We included original research papers or abstracts
of clinical trials on the use of INIs in HIV-positive patients. We
included randomized controlled trials, non-randomized trials,
retrospective analysis of these trials, cohort studies or cross-
sectional studies. Language restrictions were set on English. We
excluded in vitro and animal studies, review articles, studies with
experimental drugs currently not evaluated in clinical trials in
humans, studies on the prophylactic use of INIs and studies in
pediatric patient populations (younger than 16 years). We assessed
all titles and abstracts identified by our search and excluded
reviews or reports describing obviously different topics other than
clinical data related to INI use. Discrepancies were resolved by
consensus or by consulting a third reviewer. Of the remaining
reports, we read the abstracts and excluded reports if they dealt
with non-clinical factors or described only pharmacokinetic and
pharmacodynamic data. Case reports and studies with small
patient cohorts (n,10) were excluded and subsequently full-length
articles were retrieved from all published papers. The flow
diagram is depicted in Figure 1.
Data Extraction and Quality Assessment
All selected articles or abstract-only reports were carefully read
and analyzed. The quality assessment of the studies selected in the
systematic review is depicted in Figure 2. We assessed the strength
of evidence by using the GRADE [Grading of Recommendations
Assessment, Development and Evaluation] approach [8] (Table 2).
In this way, a body of evidence is evaluated regarding four major
domains: risk of bias, consistency, directness and precision of study
outcomes. This results in four strength of evidence grades: high,
moderate, low or insufficient.
Data Synthesis
The following data were collected: (a) basic study characteristics:
study period, prospective or retrospectively gathered data, number
of participating centers; (b) population characteristics: population
size, pre-trial antiretroviral treatment, exclusion criteria; (c)
Table 1. Main characteristics of the integrase inhibitors used in clinical practice or in clinical trials in humans.
Generic Name FDA/EMA status
Dosing
Recommendations Serum Half-life Route of Metabolisation Major Adverse Events
Raltegravir FDA/EMA approved for
therapy-naive and
experienced patients
400 mg BD - no food
restrictions
,9 hrs UGT1A1- mediated
glucuronidation
nausea and diarrhea - skin rash with
fever (rare) - CPK elevation, muscle
weakness, rhabdomyolysis - transient
elevation of serum transaminase
levels - hypersensitivity reactions,
hepatitis
Elvitegravir FDA approved for
therapy-naive patients
as part of single tablet
regimen
150 mg QD, + booster
(100 mg ritonavir or
cobicistat) - to be
taken with meals





nausea and diarrhea - headache,
insomnia - eGFR decrease when
combined with cobicistat (inhibition
of tubular secretion of creatinine)
Dolutegravir Phase III studies
ongoing
50 mg QD in INI- naive
patients, 50 mg BD in
INI-experienced
patients - no food
restrictions





nausea and diarrhea - transient
low-level increases in serum
creatinine - eGFR decrease
(inhibition of tubular secretion
of creatinine) - hypersensitivity
reactions, hepatitis
FDA (Food and Drug Administration) and EMA (European Medicines Agency) status , dosing recommendations, serum-half-life, main route of metabolization and
currently reported major adverse events are indicated.
BD = twice-daily; QD = once-daily.
doi:10.1371/journal.pone.0052562.t001
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intervention characteristics: drugs used, drug dosage, duration of
treatment and follow-up; (d) outcome parameters: virologic and
immunologic response, genotypic data of eventual drug resistance
at therapy failure, clinical and laboratory adverse events.
Data Analysis
A random-effects meta-analysis was used to investigate the
combination or interaction of this collection of independent
studies. This was performed using STATA/MP4 (release 11;
StataCorp LP, Texas USA; STATA module ‘mais’) following the
Mantel-Haenszel model to obtain weighted odds ratios (OR) and
95% confidence intervals (CI) of virological outcome data [9,10].
An OR of one indicates no difference between both groups; ORs
below one indicate benefit of INI versus the control regimen. If the
95% CI of the OR contains the value 1, there is no sufficient
evidence for a difference between both treatment groups. For the
calculation of these ORs, the virological outcome data were
normalized towards time-point (24 or 48 weeks after start of INI).
Studies reported virological outcome data based on: TLOVR
(time-to-loss-of-virological-response) (n = 2), snapshot approach
Figure 1. Prisma 2009 Flow diagram literature search and study selection. PRISMA diagram showing the different steps of systematic
review, starting from literature search to study selection and exclusion. At each step, the reasons for exclusion are indicated.
doi:10.1371/journal.pone.0052562.g001
Figure 2. Quality assessment of the selected studies in systematic review. Summary of the proportion of studies that fulfilled each quality
assessment criterion. When no clear answer could be obtained for a specific criterion, it was classified as ‘‘unclear’’. ART = Antiretroviral Treatment.
doi:10.1371/journal.pone.0052562.g002
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Table 2. Overview of studies in systematic review, grouped according to study-design and indication: regimens, population size,




(n = ) Regimen (w) Summary
ART-naive patients: INI in combination with dual NRTI GRADE: HIGH
STARTMRK [15–19] 281 282 RAL 400 mg bd + TDF/FTC vs. EFV + TDF/FTC 240 Non-inferiority of raltegravir in reaching VL,50 c/
ml (71% vs 61.3% EFV, mITT); Significantly more
rapid decline of viral load in early phase with INI;
Mean CD4 increase 374 (INI) versus 312 cells/ml
(EFV).
Protocol 004 [20–22] 160 38 RAL 100, 200, 400 or 600 mg bd + TDF/3TC vs.
EFV + TDF/3TC
240 Similar proportions of VL,50 c/ml (69% vs 63%,
mITT) in all dosages (400 mg bd single arm as from
w48) - non-inferiority for raltegravir; Similar mean
CD4 increase (302 versus 267 cells/ml); Less
frequent drug-related clinical adverse events with
raltegravir (55%) than efavirenz (76%).
SHIELD [24] 35 N RAL 400 mg bd + ABC/3TC 96 Proportion of VL,50 c/ml (mITT: 77%); Median CD4
increase 304 cells/ml; No drug-related serious
adverse events reported
GS-236-014 [26] 48 23 EVG/COBI single tablet qd+ TDF/FTC vs. EFV +
TDF/FTC
48 Non-inferiority of elvitegravir/cobicistat in
suppressing VL,50 c/ml (mITT: 90% vs 83%
treatment difference +8.4% (28.8 to +25.6%).
Treatment with EVG/COBI associated with more
rapid achievement of undetectable VL than EFV/
FTC/TDF (P,0.05 at weeks 2,4 and 8). Lower rate of
drug-related central nervous system and psychiatric
adverse events in EVG/COBI group
GS-236-0102 [25] 348 352 EVG/COBI/FTC/TDF qd vs EFV/TDF/FTC 48 Non-inferiority of QUAD (EVG/COBI/TDF/FTC) in
suppressing VL,50 c/ml (mITT 87.6% vs 84.1%;
treatment difference +3.6% CI 21.6 to +8.8%).
Treatment with QUAD associated with higher CD4
increase at 48w (239 cells/mL vs 206 cells/mL
p = 0.009). Similar numbers of patients discontinued
treatment because of an adverse event in each
group. Nausea was more common in the QUAD
group, CNS and psychiatric adverse events more
frequent with EFV
SPRING-1 [27–29] 155 50 DTG 10,25 or 50 mg + TDF/FTC or ABC/3TC vs.
EFV + TDF/FTC or ABC/3TC
48 Similar response rates (VL,50 c/ml) for all doses of
dolutegravir compared to efavirenz (mITT 87%
versus 82%); Median CD4 increase in all dolutegravir
groups were higher than efavirenz (231 cells per mL
vs 174 cells per mL; p = 0?076); No serious adverse
events related to dolutegravir
SINGLE [14] 414 419 DTG 50 mg + ABC/3TC vs. EFV/TDF/FTC 48 Significant better virological reponse of DTG/ABC/
3TC compared to EFV/TDF/FTC (mITT 88% vs 81%);
median CD4 increase significantly higher in DTG/
ABC/3TC (267 vs 208 cells/ml; p,0.001) No INI or
NRTI resistance observed in the DTG-treated group
and no serious adverse events.
GS-236-0103 [31] 353 355 EVG/COBI/FTC/TDF qd vs ATV/r + TDF/FTC 48 Non-inferiority of QUAD (EVG/COBI/TDF/FTC) in
suppressing VL,50 c/ml (mITT 89.5% vs 86.8%;
treatment difference +3.0% CI 21.9 to +7.8%).
Similar increase of CD4 count in both groups.
Similar numbers of patients discontinued treatment
because of an adverse event in each group. More
Grade 3 and 4 lab abnormalities in the ATV/r group
compared to QUAD.
SPRING -2 [30] 413 414 DTG 50 mg qd + TDF/FTC or ABC/3TC vs
RAL 400 mg bd + TDF/FTC or ABC/3TC
48 Non-inferiority of dolutegravir versus raltegravir in
reaching VL,50 c/ml (ITT 88% vs 85%). Similar
median CD4 increase (230 CD4 cells/ml).
Discontinuation due to serious adverse events 2%
in each group. No IN or NRTI resistance upon failure
in DTG group versus 1 and 4 pts in the RAL groups.
QDMRK [23] 382 388 RAL 800 mg bd + TDF/FTC vs. RAL 400 mg bd +
TDF/FTC
48 mITT: 83% in the once-daily group had virological
response compared with 89% in the twice-daily
group (difference 25?7%, 95% CI 210?7 to 20?83;
p = 0?044); Mean CD4+ increase comparable in both
groups; serious adverse events reported in 7% and
10% of resp. once-daily recipients and twice-daily
recipients.
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(n = ) Regimen (w) Summary
ART-naive patients: INI in combination with PI GRADE: MODERATE
SPARTAN [13] 63 31 RAL 400 mg bd + ATV vs. ATV/r + TDF/FTC 24 Through week 24, both arms achieved comparable
efficacy rates (ITT 74,6% versus 63,3% VL,50 c/ml)
PROGRESS [32] 101 105 RAL 400 mg bd + LPV/r vs. LPV/r + TDF/FTC 48 Non-inferiority of the study regimen at reaching
VL,40 c/ml at week 48 (ITT 81.2% versus 85.7% ;
difference 24.5%; 95% CI, 215.1% to 5.9%); Mean
CD4 increase was similar between groups.
ACTG A5262 [34] 112 N RAL 400 mg bd + DRV/r 48 DRV/r plus RAL was effective (mITT 73% VL,50 c/
ml at week 48) and well tolerated in treatment-
naive patients, but those with base-line viral load
.100,000 copies/mL had more VF and INI
resistance.
RADAR [33] 40 40 RAL 400 mg bd + DRV/r vs. DRV/r + TDF/FTC 24 mITT VL,50 c/ml at week 24 achieved in 75.0%
(RAL treated) versus 82.5%; mean CD4 increase
+143 versus 109 cells/ml
Fallon et al [83] 15 15 RAL 400 mg bd (naive) + LPV/r vs
RAL 400 mg bd (exp) + LPV/r
48 mITT: 80.0% (12/15 treatment-naive) versus 73.3%
(11/15 treatment-experienced) had VL,50 c/ml at
48 weeks; mean CD4 change 102 versus 66 cells/ml
ART-experienced patients: virological failure GRADE: MODERATE
BENCHMRK 1 and 2
[2,35]
462 237 RAL 400 mg bd + NNRTI + NRTI vs. Placebo +
NNRTI + NRTI
96 Sustained VL,50 c/ml in the combined studies of
57% (raltegravir) versus 26% (placebo) (mITT 96w);
mean CD4 increase 109 versus 45 cells/ml (P,0.001
for each study individually and the combined
studies); Frequencies and exposure-adjusted rates
of clinical adverse events and laboratory
abnormalities similar in both groups
Protocol 005 [36,37] 133 45 RAL 200, 400 or 600 mg bd + optimized BR vs.
Placebo + optimzed BR
96 Raltegravir in all doses superior than placebo in
reaching undetectable VL at double-blind phase (till
24 weeks); No dose-dependent differentiation in
the safety or antiviral activity of raltegravir; After
96weeks (RAL 400 mg bd .24w all groups) 55%
and 48% reached VL,400 c/mL and VL,50 c/ml
(mITT); There were few discontinuations of
raltegravir (4%) due to adverse events.
ANRS 139 TRIO [3] 103 N RAL 400 mg bd + ETV + DRV/r 96 mITT: 86% VL,50 c/ml at 48w; median CD4
increase 108 cells/ml. Grade 3 or 4 clinical adverse
events reported 14,6%, though only 1 patient
discontinued the regimen because of an adverse
event
Canestri et al [39] 20 N RAL 400 mg bd + ETV + optimized BR 24 mITT: 65% of patients reached VL,40 c/ml and
100% VL,400 c/ml; median CD4 increase +80cells/
ml
Nozza et al [41] 28 N RAL 400 mg bd + MVC + ETV 48 mITT/OT: At week 48, 26/28 patients achieved
VL,50 c/ml. The median CD4 increase was 267
cells/mL. No patient discontinued treatment.
Caby et al [42] 67 N RAL 400 mg bd + BR 48 At 48 weeks, 43/67 patients had complete
(VL,50 c/ml) and 16/67 incomplete (VL,400 c/ml)
suppression, while 8 patients failed (mITT). Upon
failure, 6/8 patients harbored RAL resistance
GS-183-105 [38] 205 73 EVG/RIT 20, 50 or 125 mg bd + optimized BR vs.
PI/r + optimized BR
24 mITT: Elvitegravir 50 mg was noninferior and
elvitegravir 125 mg superior compared with the PI/r
(based on DAVG24 scores). Efficacy was impacted
by activity of background agents. Similar mean CD4
increase across all treatment arms; no relationship
between elvitegravir dosage and adverse events.
GS-183-0145 [43] 361 363 EVG 150 mg qd + PI/r + NRTI vs. RAL 400 mg bd +
PI/r + NRTI
48 Elvitegravir non-inferior (59%) compared to
raltegravir (58%) in achieving complete virological
response (mITT treatment diff erence +1?1%, 95% CI
26?0 to 8?2); Median CD4 increases and proportion
of adverse events attributed to study drugs similar
in the two treatment arms
VIKING I [45,46] 27 N DTG 50 mg qd + optimized BR 24 mITT: 52% and 41% of patients treated till 24weeks
achieved VL,400 c/ml and VL, 50 c/ml; Drug
related AEs (any grade) were observed in 6 (22%)
subjects
HIV Integrase Inhibitors in Clinical Settings





(n = ) Regimen (w) Summary
VIKING II [47] 24 N DTG 50 mg bd + BR 11d After 11days of functional monotherapy (triple
resistant virus including INI), 54% of patients
reached VL,400 c/ml (mITT). No discontinuation
due to AE/lab toxicities. 17% treatment emergent
grade 3 lab abnormalities.
ART-experienced patients: switch strategy GRADE: LOW
SWITCHMRK 1 and 2 [48]353 354 RAL 400 mg bd + BR 2 LPV/r vs. BR 24 84?4% in the raltegravir group versus 90?6% in the
lopinavir-ritonavir group (mITT treatment diff
erence 26?2%, 211?2 to 21?3) had VL,50 c/ml,
leading to study stop. Majority of RAL-failures had
RAL resistance. Mean CD4 increase was small and
did not diff er between treatment groups.
SPIRAL [49] 139 134 RAL 400 mg bd + BR 2 PI/r vs. BR 48 Non-inferiority of raltegravir (mITT 89.2% versus
86.6% of patients remained free of treatment failure
[difference +2.6%; 95% CI 25.2 to +10.6]; No
differences between treatment groups in CD4
increase
EASIER ANRS 138 [50] 85 85 RAL 400 mg bd + BR 2 T20 vs. BR +2 T20 or
RAL (.24w)
48 At week 48, 90% of patients in both the immediate
and deferred groups had plasma VL,50 c/ml
(mITT); Median CD4 cell counts remained stable
during follow-up.
ODIS [55] 149 73 RAL 800 mg qd + BR 2 PI/r vs. RAL 400 mg bd +
BR 2 PI/r
24 6.4% in the oncedaily arm and 2.9% in the twice-
daily arm (mITT) experienced virological failure,
with significant higher rates in patients with prior
nucleoside reverse transcriptase inhibitor resistance
(16,2% versus 0,7% P,0,001); significant increase in
CD4 (+32 cells/mL) after switch to RAL.
RASTA [56] 21 19 RAL 400 mg bd + TDF/FTV vs. RAL 400 mg bd +
ABC/3TC
24 One virological failure in TDF/FTC arm at 24 weeks;
At 24w, a higher increase in CD4 count was
observed in arm B versus arm A (mean +62 vs 29
cells/mm3 respectively, p = 0.04).
Talbot et al [53] 28 N RAL 400 mg bd + BR 2 T20 24 26/27 patients with data at 24 weeks remained with
a VL ,50 c/ml; No significant changes, statistically
or clinically, were observed in the CD4 counts
CHEER [54] 52 N RAL 400 mg bd + BR 2 T20 24 49/52 (94.2%, confidence interval: 1.2% to 15.9%)
remained with a VL,50 c/ml 24 weeks (mITT);
mean CD4 increase of 32 cells/ml was seen after 24
weeks
Harris et al [51] 35 N RAL 400 mg bd + BR 2 T20 16 34/35 patients have HIV RNA ,50 c/ml at 16 weeks
of follow-up (mITT)
Santos et al [52] 36 N RAL 400 mg bd + BR 2 T20 48 All but 1 patient (discontinuation) maintained
VL,50 copies/mL at Weeks 24 and 48
Reliquet et al [57] 20 N RAL 400 mg bd + NVP 48 At week 48, 19/20 patients (100% undetectable VL
at start) achieved VL,50 c/ml (mITT)
ART-experienced patients: treatment intensification GRADE: INSUFFICIENT
Hatano et al [63] 15 15 RAL 400 mg bd + BR vs. Placebo + BR 48 The proportion of subjects with undetectable VL
did not differ between the 2 groups (mITT p = 0.42);
Raltegravir intensification did not have a significant
effect on immune activation or HIV-specific
responses in PBMCs or gut-associated lymphoid
tissue.
CORAL [59] 19 54 RAL 400 mg bd + BR vs. HIBC/placebo + BR 24 Compared with placebo, the addition of neither
raltegravir nor HIBC to cART for 24 weeks resulted
in a significant change in CD4 count (mITT mean
difference, 95% confidence interval [CI]: 3.09 cells/
lL, 214.27; 20.45, p = .724 and 9.43 cells/lL, 27.81;
26.68, p = .279, respectively)
ACTG A5244 [62] 25 24 RAL 400 mg bd + BR vs. placebo + BR 12 12 weeks of raltegravir intensification did not
demonstrably reduce low-level plasma viremia in
patients on currently recommended ART.
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(n = 3) or protocol-defined composite-endpoints (n = 11). In order
to reveal differences between virological efficacy and ancillary
benefits (e.g. lower toxicity, more convenient formulation), we
extracted modified intention-to-treat (mITT) as well as on-
treatment (OT) and as-treated (AT) data [11,12]. mITT includes
all patients who received at least one dose of study drug and
completed the study, missing data are considered as failures, as are
non-completers. OT includes only the patients completing the
study at the analyzed endpoint. Patient-data were censored in case
of toxicity, loss to follow-up, lack of efficacy before the endpoint is
reached and other reasons. AT is similar to OT, but includes
patients with virological failure before the endpoint is reached.
Only controlled studies with virological outcome data comparing
INI versus another compound or placebo were included. If data
were not available in the paper, authors were contacted and
invited to provide it. We assessed statistical heterogeneity using the
I-square statistic that measures the degree of inconsistency across
studies; it results in a 0–100% range quantifying the proportion of
variation in the effect, which is due to inter-study variation, with
lower values indicating more homogenous study results. We
predefined heterogeneity (I2#25% for low, 25%,I2,50% for
moderate, and I2$50% for high). Funnel plots in different
subcategories were constructed to assess bias. A pooled analysis
was made of all available data on immunological efficacy, adverse





(n = ) Regimen (w) Summary
Buzon et al [58] 45 24 RAL 400 mg bd + BR vs. BR 48 Raltegravir intensification of a three-drug
suppressive ART regimen resulted in a specific and
transient increase in episomal DNAs in a 29% of
ART-suppressed subjects; With these episomal
DNAs, immune activation was higher at baseline
and was subsequently normalized after raltegravir
intensification.
McMahon et al [65] 10 N RAL 400 mg bd + BR 4 There was no evidence in any subject of a decline in
HIV-1 RNA level (ultra-sensitive assay) during the
period of raltegravir intensification or of rebound
after discontinuation
Cesar et al [60] 10 10 RAL 400 mg bd + BR vs. Placebo + BR 48 After 48 weeks all patients remained with VL,5 c/
mL. No differences in CD4 gain were observed
between placebo and raltegravir arms (mITT 11 vs.
24 respectively, t18 = 0.586, p = 0.565); Increased
immune activation did not change after 48 weeks
Lichtenstein et al [64] 30 N RAL 400 mg bd+ BR 12 Addition of raltegravir to a suppressive ART
regimen improves some immunologic, cytokine/
chemokine, and effector memory cell parameters
(IFNc, MIP-1a; IL-2 and RANTES) in immunologic
non-responders.
Dahl et al [66] 14 9 RAL 400 mg bd + BR vs BR 12 Raltegravir intensification did not reduce intrathecal
immunoactivation or alter CSF HIV-1 RNA levels in
subjects with baseline viral suppression
ART-experienced patients: INI in combination with PI GRADE: INSUFFICIENT
Ripamonti et al [69] 27 N RAL 400 mg bd + ATV 24 After a median follow up of 7 (IQR 5–7) months, VL
was ,50 c/ml in all but one of the 27 patients (63%
undetectable VL at start); The median CD4 count
increment was 168 cells/ml.
Tsukada et al [70] 19 N RAL 400 mg bd + DRV/r 48 After a median follow up of 47 (24–102) weeks,
VL,100 c/mL detected in 16/19 patients (68%
undetectable VL at start)
Allavena et al [67] 29 N RAL 400 mg bd + PI/r 22 After a median follow-up of 22 weeks, VL,50 c/ml
in 24/29 patients (79% undetectable VL at start)
Cordery et al [68] 20 N RAL 400 mg bd + ATV 72 At week 72, 13/20 patients (100% undetectable VL
at start) achieved VL,50 c/ml (mITT) Median CD4
cell counts remained stable during follow-up.
Gardner et al [71] 39 N RAL 400 mg bd + PI 48 After median follow-up of 47 weeks, 74% and 44%
of patients reached HIV RNA,200 c/ml and ,50 c/
ml – mITT (46% HIV RNA,200 c/ml at start) in
heavily pre-treated patients. Adherence and pre-
existing PI resistance are associated with virological
failure.
GRADE level of evidence per category is added. INI-containing treatment arms are underlined.
(c)ART = (combination) antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; (w) = weeks; VL,50 = viral load or HIV RNA ,50 copies/ml; N = not
applicable; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir; COBI = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/
emtricitabine; ABC/3TC = abacavir/lamivudine; LPV = lopinavir; r = ritonavir; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor;
BR = background regimen; T20 = enfurvirtide; NVP = nevirapin; HIBC = hyperimmune bovine colostrum.
doi:10.1371/journal.pone.0052562.t002
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Results
Systematic review
The systematic review resulted in 48 eligible studies on the
clinical use of integrase inhibitors, of which 15 abstract-only
reports (Figure 1). These studies include in total more than 9400
HIV-infected patients. Of these studies, 38 (79%) described
interventions regarding raltegravir use. Elvitegravir and dolute-
gravir were respectively investigated in 5 (10%) studies each. The
average study population size was 202 (IQR 28–222), the average
study duration 48 weeks (IQR 24–48). All but four of the included
studies were prospective, the majority randomized (59%) and
multi-centered (59%). Blinding was performed in 48% of the
studies, 20 studies were single-armed (Figure 2). Study character-
istics of all studies with latest result updates and evidence levels per
category can be found in Table 2, the studies and data used in the
meta-analysis are listed in Table 3.
Meta-analysis
Subsequently a meta-analysis of virological outcome (number of
patients achieving HIV RNA below 50 copies/ml) was performed
on the 16 controlled studies that compared an INI-based regimen
with placebo or other drug classes for similar indications and in
which similar endpoints could be evaluated (same measures and
same available time-point results). This resulted in three subcat-
egories (treatment-naive patients, treatment-experienced patients
with virological failure and patients switching successful suppres-
sive therapy) and the exclusion of studies on treatment intensifi-
cation, due to the absence of comparable endpoints. The results of
the meta-analysis are visualized in Forest plots (Figure 3 and
Figure S1). Low heterogeneity in the outcome was seen in the
treatment-naive subgroup (mITT, I2 0.0%) and the patients
switching successful suppressive therapy group (mITT, I2 23.6).
Higher heterogeneity was seen in the studies for patients
experiencing virological failure (mITT, I2 83.7%), which points
to a higher inter-study variation on virological outcome (Figure
S2).
Clinical outcome in antiretroviral-naive patients
Based on our pre-defined criteria for meta-analysis, we included
ten studies on treatment naı¨ve patients. Overall, INI based
regimens showed a better virological outcome, which reached
significance in the mITT analysis (OR 0.71, 95% CI 0.59–0.86;
Figure 3A) and OT analysis (OR 0.63, 95% CI 0.47–0.84; Figure
S1A). The meta-analysis using AT data (OR 0.86, 95% CI 0.61–
1.22; Figure S1A) showed a similar but non-significant favourable
trend for INI-based regimens. For one study, no OT or AT data
could be obtained [13], for another study AT data were lacking
[14].
Comparison of INI versus NNRTI both in combination
with dual NRTI. A sub-analysis of the virological outcome data
at 48 weeks comparing INI versus NNRTI showed an OR
favoring INIs over efavirenz in the mITT meta-analysis (OR 0.67,
95% CI 0.54–0.84) and OT meta-analysis (OR 0.59, 95% CI
0.43–0.81).
In STARTMRK, raltegravir twice-daily (n = 281) was com-
pared to once-daily efavirenz (n = 282) with a backbone of
tenofovir/emtricitabine [15–19]. Raltegravir showed non-inferi-
Table 3. Study characteristics of studies included in meta-analysis (n = 1 ): regimens, population size, timepoint of analysis and




(n = ) Regimen Analysis time point (w)
ART-naive patients
STARTMRK [16] 281 282 RAL 400 mg bd + TDF/FTC vs. EFV + TDF/FTC 48
Protocol 004 [21] 160 38 RAL 100, 200, 400 or 600 mg bd + TDF/3TC vs. EFV + TDF/3TC 48
GS-236-014 [26] 48 23 EVG/COBI single tablet qd+ TDF/FTC vs. EFV + TDF/FTC 48
GS-236-0102 [25] 348 352 EVG/COBI/FTC/TDF qd vs EFV/TDF/FTC 48
SPRING-1 [28] 155 50 DTG 10,25 or 50 mg + TDF/FTC or ABC/3TC vs. EFV + TDF/FTC or ABC/3TC 48
SINGLE [14] 414 419 DTG 50 mg + ABC/3TC vs. EFV/TDF/FTC 48
GS-236-0103 [31] 353 355 EVG/COBI/FTC/TDF qd vs ATV/r + TDF/FTC 48
SPARTAN [13] 63 31 RAL 400 mg bd + ATV vs. ATV/r + TDF/FTC 24
PROGRESS [32] 101 105 RAL 400 mg bd + LPV/r vs. LPV/r + TDF/FTC 24
RADAR [33] 40 40 RAL 400 mg bd + DRV/r vs. DRV/r + TDF/FTC 24
ART-experienced patients with virological failure
BENCHMRK 1 and 2 [2] 461 237 RAL 400 mg bd + NNRTI + NRTI vs. Placebo + NNRTI + NRTI 24
Protocol 005 [36,37] 134 45 RAL 200, 400 or 600 mg bd + optimized BR vs. placebo + optimized BR 24
GS-183-105 [38] 205 73 EVG/RIT 20, 50 or 125 mg bd + optimized BR vs. PI/r + optimized BR 24
ART-experienced patients switching suppressive therapy
SWITCHMRK 1 and 2 [48] 353 354 RAL 400 mg bd + BR 2 LPV/r vs. BR 24
SPIRAL [49] 139 134 RAL 400 mg bd + BR 2 PI/r vs. BR 32
EASIER ANRS 138 [50] 85 85 RAL 400 mg bd + BR 2 T20 vs. BR +2 T20 or RAL (.24w) 24
INI-containing treatment arm is underlined.
ART = antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; VL,50 = viral load or HIV RNA ,50 copies/ml; RAL = raltegravir; EFV = efavirenz;
EVG = elvitegravir; COBI = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/emtricitabine; ABC/3TC = abacavir/lamivudine;
LPV = lopinavir; r = ritonavir; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; BR = background regimen; T20 = enfurvirtide.
doi:10.1371/journal.pone.0052562.t003
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ority based on the primary virological endpoint from 48 up to 240
weeks (mITT 48 week treatment difference +4.2%, 95% CI 21.9
to 10.3). Moreover viral decline in the early treatment phase was
significantly more rapid in the raltegravir arm. In the rare cases
resistance was observed, multiple raltegravir resistance associated
mutations were detected (Table S1). In Protocol 004, an initial
dose-ranging trial comparing raltegravir (n = 160) to efavirenz with
tenofovir/lamivudine (n = 38) as backbone, similar virological and
immunological results at 48 weeks (mITT) were observed as in
STARTMRK at all doses [20–22]. Few but high-level raltegravir
resistance was detected.
Amongst the studies with raltegravir in antiretroviral-naive
patients which could not be incorporated in the meta-analysis,
QDMRK, comparing once-daily raltegravir (800 mg qd) versus
twice-daily raltegravir (400 mg bd), yields important additional
information. Despite high levels of suppression in both arms, the
once-daily arm was inferior compared to the twice-daily arm
(mITT) [23]. This higher virological failure rate was observed
mainly in patients starting with high baseline viral load and low C-
through levels at 24 hours. Resistance was rare but more frequent
in the once-daily arm. Also not included was the uncontrolled
SHIELD study, which evaluated raltegravir in combination with
abacavir/lamivudine (n = 35) and reported a high proportion
(77%) of patients reaching undetectable viral load at 96 weeks in
mITT analysis [24].
In the GS-236-0102 phase 3 study, elvitegravir combined with
the booster cobicistat and a backbone of emtricitabine and
tenofovir (QUAD) (n = 348) was compared to efavirenz with the
same backbone (n = 352) both formulated as single tablet regimens
(STR). The QUAD STR showed non-inferiority based on the
primary virological endpoints up to 48 weeks (mITT 48 weeks
treatment difference: +3.6% CI 21.6 to +8.8%) [25]. As has been
reported for studies with raltegravir, a more rapid initial HIV
RNA decline with elvitegravir was observed compared to the
efavirenz arm. In both arms, similar small proportions of patients
developed drug resistance upon therapy failure (both arms n = 8).
In case of INI resistance in the QUAD failure group, NRTI
resistance was observed as well, while in the comparator arm the
detection of resistance was mainly limited to NNRTIs.
In the smaller GS-236-014 phase 2 study, the elvitegravir
containing QUAD STR (n = 48) was also compared to an
efavirenz containing STR (n = 23) with the same NRTI-backbone
[26]. Although more patients in the elvitegravir arm achieved an
undetectable viral load after one year of follow-up (mITT +8.4%,
95% CI 28.8 to +25.6), this was not statistically significant.
Treatment failures were rare and no drug resistance could be
assessed. The INI based regimen was well tolerated and fewer
adverse events were reported.
In SPRING-1, a phase II dose-ranging randomized trial, a third
INI dolutegravir was evaluated. Three different once-daily dosing
arms (n = 51 each) were tested against efavirenz (n = 50) with
either abacavir/lamivudine or tenofovir/emtricitabine [27–29].
Interim results at 48 weeks of follow-up provide favorable
virological outcome in all dolutegravir arms driven by better
tolerability (mITT, % of patients with HIV RNA ,50 copies/ml:
87% dolutegravir arm versus 82% efavirenz arm). In the few cases
of treatment failure, the interim analysis at 48 weeks from
SPRING-1 did not detect mutations associated with dolutegravir
resistance.
The follow-up study SPRING-2 compared dolutegravir 50 mg
(n = 413) versus raltegravir 400 mg (n = 414), both combined with
dual NRTI backbone [30]. This study was not included in the
meta-analysis since it compared two INIs. After 48 weeks, similar
proportions of patients on both INI regimens achieved undetect-
able viremia (ITT, % of patients with HIV RNA ,50 copies/ml:
88% versus 85%). In the dolutegravir treated group, no resistance
was detected upon failure, while in the raltegravir treated patients
one INI and four NRTI mutations were observed.
The SINGLE trial compared two STR in therapy-naı¨ve
patients: dolutegravir combined with abacavir/lamivudine
(n = 414) versus efavirenz combined with tenofovir/emtricitabine
(n = 419) [14]. A significantly better virological outcome after 48
weeks for the dolutegravir-treated group was reported (mITT
treatment difference +7.4%; 95% CI +2.5 to +12.3; p = 0,003),
while also a significant better immunological response (CD4
increase 267 cells/ml versus 204 cells/ml). The dolutegravir STR
was very well tolerated and no INI or NRTI resistance was
detected.
Comparison of INI versus PI both in combination with
dual NRTI. In the GS-236-0103 study, the elvitegravir
containing QUAD STR (n = 353) was evaluated against ritonavir
boosted atazanavir combined with emtricitabine/tenofovir
(n = 355) [31]. At 48 weeks, the QUAD regimen showed non-
inferiority based on suppression below 50 copies/ml (mITT
treatment difference +3.0% CI21.9 to +7.8%). In five cases in the
QUAD group, resistance was observed versus none in the boosted
PI treated group. Of those five, primary INI resistance was seen in
four and NRTI resistance in three patients.
Comparison of INI versus dual NRTI both in combination
with PI. In the search for simplification strategies, INI based
NRTI-sparing regimens have been explored. A sub-analysis of this
simplification approach indicated a favorable but non-significant
OR in favor of INI compared to 2 NRTI when both are combined
with a PI at 24 weeks using mITT data (OR 0.88, 95% CI 0.52–
1.50) (Figure 3A).
In the randomized open-label SPARTAN trial, raltegravir with
unboosted atazanavir (n = 63) was compared to ritonavir boosted
atazanavir plus tenofovir/emtricitabine (n = 31) [13]. Through
week 24, both arms achieved comparable efficacy rates (ITT % of
patients with HIV RNA ,50 copies/ml: 74.6% versus 63.3%).
The higher rates of hyperbilirubinemia with twice-daily atazanavir
and an increased development of raltegravir resistance in the INI-
treated group, prompted early termination of the study. Upon
virological failure, four out of five evaluable raltegravir treated
patients developed high-level raltegravir resistance. In the
PROGRESS trial, raltegravir with ritonavir boosted lopinavir
(n = 101) was compared to ritonavir boosted lopinavir (n = 105)
with tenofovir/emtricitabine [32] and reported non-inferiority of
the study regimen at reaching HIV RNA ,40 copies/ml at week
48 (ITT, 81.2% versus 85.7%; difference 24.5%; 95% CI,
Figure 3. Forest Plot of mITT meta-analyses. Panel A: Forest plot showing the meta-analysis of mITT data extracted from studies with therapy-
naı¨ve patients. Besides an overall analysis, three sub-analyses for three different comparisons are depicted. The black line indicates OR = 1, signifying
no benefit of the INI arm compared to the non-INI arm. The dotted line shows the odds ratio of all included studies. The individual odds ratios as well
as the proportionate weight in the overall analysis are shown in the right column. Panel B: Forest plot showing the meta-analysis of mITT data
extracted from studies with ART-experienced patients in case of virological failure. Panel C: Forest plot showing the meta-analysis of mITT data
extracted from studies with ART-experienced patients switching with suppressed viral load. mITT = modified intention-to-treat; ART = antiretroviral
treatment; INI = integrase inhibitor; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; T20 = enfuvirtide: OR = odds
ratio.
doi:10.1371/journal.pone.0052562.g003
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215.1% to 5.9%). Upon virological failure, two out of four
evaluable raltegravir treated patients developed high-level ralte-
gravir resistance.
The randomized open-label RADAR trial, where raltegravir
with ritonavir boosted darunavir (n = 40) was compared with
ritonavir boosted darunavir and tenofovir/emtricitabine (n = 40),
reported inferior virological outcome for the raltegravir containing
regimen after 24 weeks (mITT 75% versus 82.5% of patients with
HIV RNA ,50 copies/ml) [33].
The ACTG A5262 trial evaluating raltegravir with ritonavir
boosted darunavir (n = 112) could not be included in the meta-
analysis due to lack of a control arm [34]. Unexpected high levels
of virological failure were observed at 48 weeks (mITT 26% or 28
on 112 subjects). Virologic failure and the emergence of INI
resistance upon failure was associated with a baseline viral load
.100.000 copies/ml. Of note, in this trial a high percentage of
patients harbored NRTI resistance mutations in their viral
population at baseline, which may serve as an indicator of
undisclosed treatment experience or more extensive archived
transmitted resistance than detected using regular pol resistance
tests.
Clinical outcome in treatment-experienced patients with
virological failure
Data from three studies on ART-experienced patients with
virological failure could be incorporated in the meta-analysis.
Overall, a statistical significant OR in favour of INI use in this
population was observed in the mITT meta-analysis (OR 0.27;
95% CI 0.11–0.66) (Figure 3B). The meta-analyses using OT data
(OR 0.28, 95% CI 0.20–0.38) and AT data (OR 0.16, 95% CI
0.04–0.61) included two studies and confirmed this result (Figure
S1B). The higher I2 (mITT: 83.7%) and the Funnel plot (Figure
S2B) point to a difference in study outcome, most likely influenced
by differences in trial design and analyses.
Comparison of INI versus placebo both in combination
with optimized background. In the BENCHMRK 1 and 2
trials comparing raltegravir (n = 459) to placebo (n = 237) in
patients experiencing therapy failure, superior and sustained viral
suppression was observed up to 96 weeks (mITT, 24 weeks: 62%
versus 33% virological suppression, p,0.001) [2,35]. The majority
of virus isolates of the raltegravir failure patients harbored
integrase resistance mutations, most of which were already
detected by 24 weeks of therapy. In the Protocol 005 study, the
efficacy of several raltegravir dosages (200 mg, 400 mg or 600 mg
bd) (n = 134) with optimized background versus placebo (n = 45)
were evaluated in highly experienced patients with HIV RNA
.5000 copies/ml [36,37]. At 24 weeks, 62.0% in all raltegravir
treated groups versus 11.3% in the placebo group reached an
undetectable viral load (mITT). Integrase mutations were
observed in 35/38 INI treated patients failing therapy.
Comparison of INI versus PI both in combination with
optimized background. In the GS-183-105 dose ranging
study, elvitegravir plus optimized background regimen was
compared with ritonavir boosted PI plus optimized background
regimen (n = 63) in predominantly high PI experienced patients
[38]. In the 50 mg qd arm (n = 75) elvitegravir was non-inferior
while in the 125 mg arm (n = 73) elvitegravir was superior at
reaching successful virological outcomes after 24 weeks (mITT
time-weighted average change in log10 HIV-1 RNA (DAVG)
treatment difference: 20.42, 95% CI 20.77 to 20.06, p = 0.021).
This time-weighted endpoint has not been further validated in
other clinical trials. No OT and AT data could be extracted for
this study.
A sub-set of additional trials were reviewed but could not be
included in the meta-analysis for various reasons. Three uncon-
trolled trials evaluated raltegravir in treatment-experienced
patients in combination with other relatively new compounds.
The first study is an open-label study describing the use of
raltegravir with etravirine (400 mg bid) and an optimized
background in patients experiencing treatment failure with
darunavir (n = 20) [39]. 65% of participating patients obtained
viral suppression at week 24 (mITT). The second study is ANRS
139 TRIO, which combined raltegravir and etravirine with
ritonavir boosted darunavir (n = 103) in highly treatment-experi-
enced patients experiencing virological failure. In this landmark
study, the combination of three new compounds resulted in - at
that time - fascinating high virological suppression rates (mITT:
86% at 48 weeks) among treatment-experienced patients and these
results persisted up to 96 weeks [3,40]. Lastly, raltegravir in
combination with etravirine and maraviroc (n = 28) was tested in
an uncontrolled study among patients experiencing therapy
failure. This approach resulted in high levels of virological
suppression (mITT: % of patients HIV RNA ,50 copies/ml:
92% at 48 weeks) and no virological failure [41].
Functional mono-therapy with raltegravir in triple-resistant
patients (n = 67) was evaluated in one observational trial and
showed high efficacy at 48 weeks (mITT: 64% of patients with
HIV RNA ,50 copies/ml) [42]. Raltegravir resistance was
observed in all patients experiencing virological failure.
The GS-183-0145 study compared once-daily elvitegravir
versus twice-daily raltegravir in combination with a fully active
ritonavir boosted PI and a second agent in patients with virological
failure [43]. This study could not be included in the meta-analysis
because of comparison of two INI. Elvitegravir was non-inferior to
raltegravir regarding virological response at 48 weeks (mITT). In
case of failure, HIV-1 integrase resistance patterns by both drugs
were comparable, indicating a similar genetic barrier and cross-
resistance between both drugs [44].
The VIKING trials evaluating dolutegravir in raltegravir
treatment-experienced patients could not be included in the
meta-analysis due to their uncontrolled design [45–47]. In
VIKING I dolutegravir 50 mg once daily (n = 27) and in VIKING
II dolutegravir 50 mg twice daily (n = 24) were applied as
functional mono-therapy for 10 days, followed by a subsequent
replacement of the failing regimen by an optimized backbone. Use
of dolutegravir in these cohorts resulted in a very high level of
virological suppression at day 11 (mITT HIV RNA ,50 copies/
ml: 78% respectively 96%). Persistent viral suppression was
observed in 41% respectively 52% of these highly experienced
patients at week 24. On 15 paired viral isolates from day 1 and day
11 of VIKING II, 3/15 patients harboured additional raltegravir
associated mutations. It could not be distinguished whether those
mutations had been selected during initial raltegravir treatment or
de novo during subsequent dolutegravir use [47].
Clinical outcome in treatment-experienced patients with
suppressed viral load
Three studies on ART-experienced patients switching to INI
while virologically suppressed were included in the meta-analysis:
the analysis based on mITT data indicated a non-significant
unfavourable OR when an antiretroviral drug was switched to an
INI (OR 1.43; 95% CI 0.89–2.31) (Figure 3C). The meta-analysis
based on AT data (OR 1.73, 95% CI 1.01–2.97) demonstrates
inferiority after such switch (Figure S1C).
Comparison of INI versus PI both in combination with
dual NRTI. In the SWITCHMRK 1 and 2 studies (n = 347
both arms), a switch from ritonavir boosted lopinavir towards
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raltegravir based ART was evaluated compared to continuation of
the lopinavir based therapy [48]. Baseline genotyping was not
performed as patients had an undetectable viral load at screening.
Archived resistance data were not taken into account. The studies
were terminated prematurely because non-inferiority of raltegravir
to ritonavir boosted lopinavir was not established at week 24
(mITT: treatment difference 26.2%, 95% CI 211.2 to 21.3).
The lower success rate in the raltegravir arm was most likely due
to inclusion of patients with a history of therapy failure and pre-
existing resistance against the NRTI backbone. Patients without
previous virological failure had similar virological response rates at
week 24 in both arms. The majority of the assessable patients who
rebounded on raltegravir-based therapy harbored raltegravir
resistant virus.
In SPIRAL, a second open-label trial, a switch of ritonavir
boosted PI towards raltegravir (n = 139) versus continuation of the
ritonavir boosted PI (n = 134) was evaluated in patients with well
documented treatment history and long-term virological suppres-
sion [49]. In the mITT analysis at week 32, the switch from any
ritonavir boosted PI to raltegravir in patients with undetectable
viral load resulted in comparable high rates of virological
suppression. Low-level raltegravir resistance was observed in only
one patient.
Comparison of INI versus enfuvirtide both with
background regimen. In the EASIER-ANRS 138 trial two
switch strategies were compared: one group switched immediately
to raltegravir (n = 85), the second group continued the low genetic
barrier drug enfuvirtide and switched only after 24 weeks (n = 85).
When analyzing the mITT 24 week data, the switch from
enfuvirtide to raltegravir in heavily pretreated patients with a viral
load ,400 copies/ml at inclusion, resulted in similar rates of viral
suppression [50]. No raltegravir resistance was detected upon
virological failure.
Four smaller observational single-armed studies – hence not
include in the meta-analysis - evaluated the switch from enfuvirtide
to raltegravir in patients with an undetectable viral load and
reported high virological success rates at weeks 16 to 48 [51–54].
The ODIS trial evaluated two dosage schemes of raltegravir –
not included in the meta-analysis - while switching from a protease
inhibitor and found that the 800 mg once daily arm (n = 149) had
higher rates of virological failure at 24 weeks compared to 400 mg
twice-daily (n = 73). In patients with prior NRTI resistance,
significant higher failure rates were seen in both arms [55].
RASTA (Raltegravir Simplification for Toxicity or Adverse events)
compared switching to raltegravir 400 mg either with tenofovir/
emtricitabine (n = 21) or with abacavir/lamuvidine (n = 19) in
patients on PI, NNRTI or NRTI-based therapy with suppressed
viral load and found comparable virological suppression rates at
24 weeks. Only one patient experienced therapy failure after
switch [56]. Anecdotal data from another small study (n = 20)
which could not be included in the meta-analysis, showed high
virological suppression up to 48 weeks in 96% of patients following
regimen simplification towards a low genetic barrier regimen with
raltegravir plus nevirapine (n = 20). Prior to the simplification,
these patients were long term suppressed on a regimen containing
nevirapine most likely without a history of therapy failure [57].
Although several studies have been performed investigating the
intensification effect of adding an INI to a successful regimen, the
body of evidence from those studies is graded as insufficient [58–
66]. The heterogeneous nature of the studies, using different
outcome measures to assess clinical outcome, residual immune
activation and viral replication, and the duration of intensification
makes comparison and inclusion in a meta-analysis impossible.
Five other uncontrolled studies describing a switch to raltegravir
and boosted or unboosted PI reported good results but the
evidence graded as insufficient [67–71]. A varying percentage of
participants with an undetectable viral load at start of those studies
(63% to 100%), different outcome measures and study duration,
all hampered uniform conclusions.
Pooled analysis of immunological efficacy, adverse
events and emergence of drug resistance
When assessing the immunological response after start of INIs,
the majority of the controlled studies with raltegravir, elvitegravir
or dolutegravir indicate a similar median CD4 increase compared
to other regimens. However, in therapy-naive patients, GS-236-
0102 (48w), SINGLE (48w) and the long-term follow-up of
STARTMRK (240w), all reported significantly higher CD4
increments compared to efavirenz-based therapies [14,19,25]. In
the subgroup of treatment-experienced patients with virological
failure, use of raltegravir resulted in significant better immuno-
logical outcome in BENCHMRK 1 and 2 compared to placebo
(96w) [35]. ODIS reported similar significant results after
switching to raltegravir from a boosted PI (24w) [55].
The INIs are generally well tolerated and rarely Grade 3 or 4
treatment-emerging adverse events are reported. Compared to
efavirenz, discontinuation from INIs due to clinical adverse events
is infrequent, while compared to PIs, less severe and life-
threatening laboratory abnormalities are observed. An overview
of the major adverse events of all INIs can be found in Table 1.
In case of treatment failure in therapy-naive patients, few but
high-level raltegravir and elvitegravir resistance was observed,
which often conferred cross-resistance to these drugs. No
resistance for dolutegravir in this patient population was detected.
When combined with dual NRTI, the occurrence of raltegravir or
elvitegravir resistance-associated mutations (RAM) was associated
in 50% of cases with resistance to NRTI (Table S1).
Discussion
We performed a systematic review on all published clinical data
concerning integrase inhibitors and subsequently meta-analyses on
the virological outcome of those studies which included a
controlled arm. Based on the meta-analyses, treatment with INIs
in combination with dual NRTI showed to be more beneficial for
treatment-naive patients compared to other currently used
treatment strategies. Also in treatment-experienced patients with
virological failure, use of INIs proved to be beneficial as well.
However, in successfully treated patients with a history of therapy
failure, switching a high genetic barrier drug towards an INI was
not supported. More in depth, the following indications for use of
integrase inhibitors can be summarized:
Initial therapy
The meta-analysis shows a significant OR in favor of INI
combined with dual NRTI based on mITT and OT data, with a
similar favorable trend when AT data are used. As both mITT
and OT based meta-analyses show a similar significant OR, the
clinical benefit of INIs is not only driven by improved tolerability,
but also by higher antiviral efficacy. The non-significance of the
AT-based meta-analysis can be due to small differences between
OT and AT study populations, or might be influenced by the non-
availability of AT data from a large dolutegravir trial.
In recent European and US treatment guidelines, raltegravir
with a tenofovir/emtricitabine backbone is listed among the
preferred regimens for antiretroviral-naive HIV infected individ-
uals [4,5,72]. This is supported by the meta-analyses. Raltegravir
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showed comparable high virological efficacy compared to
efavirenz as first line antiretroviral regimen, but was found to be
superior driven by its good toxicity profile and tolerability [17,18].
Besides its good tolerability, raltegravir has a limited risk for drug-
drug interactions [73,74]. Disadvantages of raltegravir are the
non-availability of a single tablet regimen and the twice-daily
dosing schedule, as supported by the QDMRK study [23].
Raltegravir showed a low genetic barrier to drug resistance upon
failure. The emergence of raltegravir resistance was infrequent,
but often of high-level (at least two INI RAMs) and transferring
cross-resistance to elvitegravir, confirming resistance profiles
observed in earlier vitro studies [75].
More recently developed INIs like elvitegravir and dolutegravir
hold promise as part of a single tablet regimen (STR) in first-line
therapy. Boosted elvitegravir as part of a STR revealed promising
results in two large trials, but caution is needed because of
increased INI and NRTI resistance. A similar low genetic barrier
to drug resistance upon failure was seen for elvitegravir.
Raltegravir and elvitegravir based regimens showed comparable
or superior immunological response compared to other regimens.
Dolutegravir combined with abacavir/lamuvidine has been the
first combination reported to be virologically and immunologically
superior compared to an efavirenz-based regimen. No drug
resistance was detected suggesting a high genetic barrier to
resistance development.
In this patient population, novel treatment strategies have been
explored, such as the combination of INI with a PI, sparing the
NRTIs. Individual studies are underpowered or failed to show
superiority. Also the mITT, OT and AT-based meta-analysis
failed to show significant odds ratios in favor of these nucleoside-
sparing regimens. For stronger conclusions, more data are needed.
Currently a large trial evaluating this concept (NEAT-001,
tenofovir/emtricitabine/boosted darunavir versus raltegravir/
boosted darunavir) is underway.
Virological failure
The meta-analyses demonstrate convincing evidence for a
treatment change towards a regimen containing raltegravir or
elvitegravir compared to placebo and PI in PI pre-treated
individuals with virological failure, based on mITT as well as
OT and AT data. For dolutegravir, no randomized trials were
available to include in the meta-analysis. Cross-resistance observed
in these studies suggests no additional value for sequential use of
raltegravir and elvitegravir. In contrast, dolutegravir has limited
cross-resistance to other INIs based on a recent report, which
could infer a potential role for this drug in INI-experienced
patients depending on the resistance profile [45–47,76,77]. A
timely switch or even interruption of raltegravir or elvitegravir
may prevent accumulation of resistance and should be considered
in order to maximize the potential effect of dolutegravir [78].
Similar or superior immunological response was observed for
raltegravir and elvitegravir based regimens compared to other
regimens.
Regimen simplification
Switching from enfuvirtide to raltegravir resulted in high levels
of durable suppression in several uncontrolled trials [51–54]
indicating that substitution of a low genetic barrier component of
combination antiretroviral therapy by raltegravir in patients with
documented or suspected drug resistance can be safely performed
[50]. In contrast, the switch from a high genetic barrier PI towards
raltegravir in a similar population resulted in a unfavorable OR in
the OT-based meta-analysis, and thus higher levels of therapy
failure in the raltegravir arm. When adding the effect of adherence
and tolerability (mITT), the unfavorable effect was less evident.
Two major studies revealed conflicting results possibly influenced
by duration of suppression and documentation of treatment
history [48,49]. The results indicate that when switching
virologically suppressed patients, individual patient management
is needed to assess history of treatment failure, available resistance
profiles and duration of the current suppressive regimens in order
to perform a safe switch.
Limitations of the systematic review and meta-analysis
One of the limitations of this systematic review and meta-
analysis are potential variations in efficacy between the individual
INIs compared in similar settings, inherent to the study
methodology. Furthermore, the virological outcome data were
obtained following different protocols. However, direct compar-
ison of these methodologies has not revealed major differences in
outcome [79–81]. The SINGLE trial could not be incorporated in
the AT meta-analysis for therapy-naive patients, since the number
of patients failing combination antiretroviral therapy during the
study were not reported so far. In reviewing the current literature
on the clinical use of INIs, it becomes obvious that certain clinical
questions cannot be answered because of insufficient evidence due
to the lack of controlled studies. One of these gaps concerns effect
of treatment intensification. Another gap concerns use of INI
during pregnancy, since good tolerability and rapid decline of HIV
RNA in the plasma suggests a place for integrase inhibitors in this
setting [82]. However, there is no evidence from large trials on
efficacy and teratogenicity. Similarly, insufficient data are avail-
able to include raltegravir in standard post exposure prophylaxis
regimens. With the anticipated arrival of studies with new
available INIs these gaps could be closed. Finally, the review
was restricted to English-language reports.
Conclusion
The meta-analyses positioned INI as a preferred drug in the
setting of treatment-naive and as beneficial addition in treatment-
experienced patients with virological failure, based on virological
efficacy. Careful use of INI when replacing a high genetic barrier
PI is warranted. The perspectives of new single tablet regimens
containing elvitegravir or dolutegravir taken in the absence of food
restrictions hold promise for broad use in first line regimens. In
general, the addition of the integrase inhibitor class to our
armamentarium has strengthened cART regimens, and further
rational use can preserve future therapeutic options.
Supporting Information
Figure S1 Forest Plots of OT/ATmeta-analyses. Panel A:
Forest plot showing the meta-analysis of OT and AT data
extracted from studies with therapy-naı¨ve patients. Panel B: Forest
plot showing the meta-analysis of OT and AT data extracted from
studies with ART-experienced patients in case of virological
failure. Panel C: Forest plot showing the meta-analysis of OT and
AT data extracted from studies with ART-experienced patients
switching with suppressed viral load. OT = on-treatment; AT = as-
treated; ART = antiretroviral treatment; INI = integrase inhibitor;
(N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = -
protease inhibitor; T20 = enfuvirtide: OR = odds ratio.
(TIF)
Figure S2 Funnel Plots of the mITT meta-analyses. A
funnel plot is a scatterplot of treatment effect against a measure of
study size. It is used as an aid to detect bias or systematic
heterogeneity. A symmetric inverted funnel shape arises from a
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‘well-behaved’ data set, in which bias is unlikely while an
asymmetric funnel indicates a relationship between treatment
effect and study size. The three funnel plots shown for this
systematic review and meta-analyses are based on mITT data and
are all symmetric. Panel A: Funnel plot for the meta-analysis of
mITT data extracted from studies with therapy-naı¨ve patients.
Panel B: Funnel plot for the meta-analysis of mITT data extracted
from studies with ART-experienced patients in case of virological
failure. Larger mathematical differences, small number of studies
and small population size in some studies may skew the plot. Panel
C: Funnel plot for the meta-analysis of mITT data extracted from
studies with ART-experienced patients switching with suppressed
viral load. mITT = modified intention-to-treat.
(TIF)
Table S1 Overview of resistance data in the controlled
studies on INI use. Of the controlled studies on INI use in
clinical settings, data were extracted on emergence of drug
resistance. The endpoint of data-extraction, as well as the
population size in the INI-arm and control arm are reported,
besides the number of patients experiencing treatment failure in
each arm. For each drug class, the proportion of patients
harboring viruses with resistance-associated mutations is indicated
in relation to the evaluable patient samples. INI = integrase
inhibitor; CTR = control arm; (w) = weeks; VF = virological fail-
ure; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir;
DTG = dolutegravir; (N)NRTI = (non-) nucleoside reverse tran-
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